Sector News

ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor

March 5, 2015
Life sciences
(GLOBE NEWSWIRE) – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal diseases, is pleased to announce that Joseph Markoff, Ph.D., M.D. has joined the Company as Scientific Advisor. Dr. Markoff will report to Paul G. Howes, Executive Chairman of ThromboGenics Inc., and work with the Medical Affairs team in the U.S. and the global Clinical Development team.
 
Dr. Markoff has over 35 years of experience as an ophthalmic surgeon at the Wills Eye Hospital in Philadelphia, PA. He has directed the hospital’s Visual Physiology service for the past 32 years and also holds the rank of Attending Surgeon and Clinical Professor of Ophthalmology at Thomas Jefferson University Medical School.
 
Dr. Markoff founded Philadelphia Eye Associates, a leading private eye care practice in the Philadelphia area. From February 2010 till recently, he assumed the role as Global Director for Scientific Affairs in Ophthalmology at Merck & Co., Inc.
 
Dr. Markoff has conducted over 50 clinical trials during his career sponsored by companies such as Alcon, Allergan, Pfizer, Pharmacia and Merck & Co.
 
Paul Howes, Executive Chairman of ThromboGenics, Inc. said: “Joseph Markoff adds vast experience and knowledge in ophthalmology, particularly in the retinal space, to the ThromboGenics team. I expect his expertise to prove hugely valuable as we roll-out the results of on-going real-world clinical studies on treatment of symptomatic VMA with JETREA® and embark on new indications such as diabetic retinopathy.”
 
Source: ThromboGenics

Related News

September 30, 2020

Johnson & Johnson signs on Michigan’s Grand River to help with COVID-19 vaccine finishing work

Life sciences

With all eyes on the hunt for a COVID-19 vaccine, drugmakers like New Jersey’s Johnson & Johnson are scouring the market for manufacturing partners to help meet what would be […]

September 30, 2020

Takeda taps Elektrofi’s microparticle delivery platform for potential subq plasma offerings

Life sciences

Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies. Takeda will assess Elektrofi’s drug delivery platform using […]

September 29, 2020

Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion

Life sciences

Novo Nordisk wants the heart disease community to join the diabetes conversation. As Type 2 diabetes drugs nab approvals for reduced cardiovascular risks—including Novo’s own Ozempic and Victoza—the need to […]